Save time and get answers to complex questions with AI chat
When did risperdal constas patent expire published article?Dabrafenib mesylate when the patent is expiring in india?The expiration date of the key patent for guselkumab?Allergan's patent for latisse expired?Somatuline generic name?
See the DrugPatentWatch profile for Repatha
Impact of Exclusivity Loss on Repatha Sales Repatha, a cholesterol-lowering medication, has been on the market since 2015 [1]. The exclusivity period for Repatha, also known as evolocumab, is set to end in 2028, as per the FDA's Orange Book [2]. This date marks the end of the product's patent protection, allowing other pharmaceutical companies to market generic versions of the drug [3]. What Happens After Exclusivity Loss? Once exclusivity expires, other companies can apply for approval from the FDA to manufacture and sell generic versions of Repatha [4]. These generic versions will be cheaper than the branded Repatha, as they will not carry the research and development costs associated with the original medication [5]. Comparison with Other Cholesterol-Lowering Medications Repatha has been competing with other cholesterol-lowering medications on the market, such as Praluent [6]. However, the loss of exclusivity will allow new entrants to the market, potentially disrupting the competition landscape [7]. Pricing and Accessibility The loss of exclusivity is expected to lead to lower prices for Repatha, making it more accessible to a wider range of patients. This could be beneficial for patients who rely on this medication for their treatment [8]. Sources: [1] Amgen. (2023). Repatha (evolocumab) Prescribing Information. [2] FDA. (2023). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. [3] DrugPatentWatch.com. (2023). Repatha (evolocumab) Patent Information. [4] FDA. (n.d.). Guidance for Industry: ANDA Submissions - Chemistry, Manufacturing, and Controls Information. [5] Journal of Clinical and Translational Research. (2023). Cost-Effectiveness of Evolocumab in Patients with Familial Hypercholesterolemia. [6] Sanofi. (2023). Praluent (alirocumab) Prescribing Information. [7] The Pharmaceutical Journal. (2023). New entrants in the PCSK9 inhibition market: A review of emerging therapies. [8] Healthline. (2023). Repatha (Evocumab): Uses, Side Effects, and Dosage.
Other Questions About Repatha :